Loading
The translational scientist behind the aromatase inhibitor era and the Ki67 response test used in POETIC.
Mitch Dowsett's laboratory established the pharmacology of aromatase inhibitors and the biomarker work that supported the ATAC trial, and defined Ki67 change after two weeks of endocrine therapy as a predictor of outcome (POETIC). He chaired the International Ki67 Working Group and led the IMPACT and POETIC trials with Ian Smith. His current work focuses on endocrine resistance biology and biomarker standardisation.
Shares The Institute of Cancer Research, The Royal Marsden, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs) and the tag breast.
Shares The Institute of Cancer Research, HR-positive / HER2-negative breast cancer and the tag breast.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.